{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:59:26Z","timestamp":1793401166492,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008131","name":"Rheinische Friedrich-Wilhelms-Universit\u00e4t Bonn","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008131","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world data on intraocular inflammation (IOI) following aflibercept 8\u00a0mg is limited. We report on a cluster of 12 eyes with aflibercept 8\u00a0mg-associated IOI detected at three centres between July 2024 and June 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Primary outcome measures of the retrospective observational study were the classification of severity according to the SUN classification and the determination of the incidence of aflibercept 8\u00a0mg-associated IOIs. The inclusion criterion was on-label therapy in treatment-naive and patients switched to aflibercept 8\u00a0mg who developed sterile inflammation within 1 to 14 days after injection without a history of uveitis. Data was collected by means of medical history, clinical biomicroscopic examination, optical coherence tomography and fluorescein angiography. The incidence was calculated based on the number of injections performed at the three centres between July 2024 and March 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The case series comprises 12 eyes from 10 patients (7 women, 3 men) with post-injection IOI after an average of 1.9 days (SD: 0.6); nAMD (80.0%) \/ DME (20.0%). IOI occurred on average after 2.3 injections (SD: 1.6), with 91.7% pretreated without IOI event (including aflibercept 2\u00a0mg (66.7%)). Anterior uveitis developed in 16.7%, intermediate uveitis in 66.7% and posterior uveitis in 16.7%. The incidence was 1.4% per aflibercept 8\u00a0mg injection (11 eyes out of 775 injections; 95% CI: 0.6\u20132.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Initial real-world data indicate a slightly increased risk of IOIs with aflibercept 8\u00a0mg compared to the pivotal studies, some of which are fulminant and difficult to distinguish from endophthalmitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00768-0","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T03:03:27Z","timestamp":1765163007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intraocular inflammation following aflibercept 8\u00a0mg: real-world data from a multicentre retrospective observational study"],"prefix":"10.1186","volume":"12","author":[{"given":"Lea-Noelle","family":"Stoehr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Wakili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warda","family":"Darwisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Seufert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Finger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Szurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris V.","family":"Stanzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"issue":"10432","key":"768_CR1","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, et al. Intravitreal Aflibercept 8\u00a0mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet. 2024;403(10432):1153\u201363.","journal-title":"Lancet"},{"issue":"10432","key":"768_CR2","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal Aflibercept 8\u00a0mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403(10432):1141\u201352.","journal-title":"Lancet"},{"issue":"5","key":"768_CR3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/IAE.0000000000000801","volume":"36","author":"PD Williams","year":"2016","unstructured":"Williams PD, Chong D, Fuller T, Callanan D, NONINFECTIOUS VITRITIS AFTER, INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS. Variations in rates and presentation by medication. Retina. 2016;36(5):909\u201313.","journal-title":"Retina"},{"issue":"1","key":"768_CR4","doi-asserted-by":"publisher","first-page":"100111","DOI":"10.1016\/j.xops.2021.100111","volume":"2","author":"N Eter","year":"2022","unstructured":"Eter N, Singh RP, Abreu F, Asik K, Basu K, Baumal C, et al. YOSEMITE and RHINE: phase 3 randomized clinical trials of faricimab for diabetic macular edema: study design and rationale. Ophthalmol Sci. 2022;2(1):100111.","journal-title":"Ophthalmol Sci"},{"issue":"10326","key":"768_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"issue":"5","key":"768_CR6","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/IAE.0000000000004394","volume":"45","author":"A Montesel","year":"2025","unstructured":"Montesel A, Sen S, Preston E, Patel PJ, Huemer J, Hamilton RD, et al. INTRAOCULAR INFLAMMATION ASSOCIATED WITH FARICIMAB THERAPY: One-Year Real-World outcomes. RETINA. 2025;45(5):827.","journal-title":"RETINA"},{"key":"768_CR7","doi-asserted-by":"crossref","unstructured":"Callanan D, Khurana RN, Maturi RK, Patel S, Wykoff CC, Eichenbaum D, Khanani AM, Hassan T, Badger H, Mehta S, Le G, Attar M, Seal J, Li X-Y. Impact of modifying abicipar manufacturing process in patients with neovascular age-related macular degeneration: MAPLE study results. Clin Ophthalmol. 2023;17:1367\u20131384.","DOI":"10.2147\/OPTH.S405994"},{"issue":"10","key":"768_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.ophtha.2020.03.035","volume":"127","author":"D Kunimoto","year":"2020","unstructured":"Kunimoto D, Yoon YH, Wykoff CC, Chang A, Khurana RN, Maturi RK, et al. Efficacy and safety of abicipar in neovascular Age-Related macular degeneration: 52-Week results of phase 3 randomized controlled study. Ophthalmology. 2020;127(10):1331\u201344.","journal-title":"Ophthalmology"},{"issue":"3","key":"768_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/ICU.0000000000000154","volume":"26","author":"HF Fine","year":"2015","unstructured":"Fine HF, Despotidis GD, Prenner JL. Ocular inflammation associated with antivascular endothelial growth factor treatment. Curr Opin Ophthalmol. 2015;26(3):184\u20137.","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"768_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00347-021-01321-8","volume":"118","author":"FG Holz","year":"2021","unstructured":"Holz FG, Heinz C, Wolf A, Hoerauf H, Pleyer U. Intraokulare Entz\u00fcndungen Bei Brolucizumab-Anwendung: Patientenmanagement \u2013 Diagnose \u2013 Therapie. Ophthalmologe. 2021;118(3):248\u201356.","journal-title":"Ophthalmologe"},{"issue":"9","key":"768_CR11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/ceo.14175","volume":"50","author":"DA Jabs","year":"2022","unstructured":"Jabs DA, McCluskey P, Palestine AG, Thorne JE. Group TS of UN (SUN) W. The standardisation of uveitis nomenclature (SUN) project. Clin Exp Ophthalmol. 2022;50(9):991\u20131000.","journal-title":"Clin Exp Ophthalmol"},{"key":"768_CR12","doi-asserted-by":"crossref","unstructured":"abs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol [Internet]. 2005 Sep [cited 2025 Oct 23];140(3):509\u2013516. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16196117\/","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"768_CR13","doi-asserted-by":"crossref","unstructured":"Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology [Internet]. 1985 Apr [cited 2025 Oct 23];92(4):467\u2013471. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/4000641\/","DOI":"10.1016\/S0161-6420(85)34001-0"},{"issue":"5","key":"768_CR14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/s-2005-858231","volume":"222","author":"J Gb","year":"2005","unstructured":"Gb J, Ku PS. undefined. [Recommendation for the implementation of intravitreal injections\u2013statement of the German retina society, the German society of ophthalmology (DOG) and the German professional association of ophthalmologists (BVA)]. Klin Monbl Augenheilkd. 2005;222(5):390\u20135.","journal-title":"Klin Monbl Augenheilkd"},{"key":"768_CR15","doi-asserted-by":"publisher","unstructured":"Binder\u202fKE, Bleidi\u00dfel\u202fN, Charbel\u202fIssa\u202fP, Maier\u202fM, Coulibaly\u202fLM. Noninfectious intraocular inflammation after intravitreal aflibercept. JAMA Ophthalmol. 2025;143(6):499\u2013506. https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.0969","DOI":"10.1001\/jamaophthalmol.2025.0969"},{"issue":"1","key":"768_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","volume":"7","author":"WJ Anderson","year":"2021","unstructured":"Anderson WJ, da Cruz NFS, Lima LH, Emerson GG, Rodrigues EB, Melo GB. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J Retina Vitreous. 2021;7(1):37.","journal-title":"Int J Retina Vitreous"},{"issue":"1","key":"768_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/s12886-024-03788-w","volume":"24","author":"L Hoffmann","year":"2024","unstructured":"Hoffmann L, Michels S, Eandi C, Karam MA, Figueiredo EC, de O, Hatz K. Aflibercept high-dose (8\u00a0mg) related intraocular inflammation (IOI) \u2013 a case series. BMC Ophthalmol. 2024;24(1):520.","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"768_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10384-024-01107-w","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto H, Hoshino J, Numaga S, Mimura K, Asatori Y, Akiyama H. Retinal vasculitis after intravitreal Aflibercept 8\u00a0mg for neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024;68(5):531\u20137.","journal-title":"Jpn J Ophthalmol"},{"issue":"10","key":"768_CR19","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/jphp.12765","volume":"69","author":"T Uchino","year":"2017","unstructured":"Uchino T, Miyazaki Y, Yamazaki T, Kagawa Y. Immunogenicity of protein aggregates of a monoclonal antibody generated by forced shaking stress with siliconized and nonsiliconized syringes in BALB\/c mice. J Pharm Pharmacol. 2017;69(10):1341\u201351.","journal-title":"J Pharm Pharmacol"},{"issue":"7","key":"768_CR20","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.xphs.2019.02.002","volume":"108","author":"E Krayukhina","year":"2019","unstructured":"Krayukhina E, Yokoyama M, Hayashihara KK, Maruno T, Noda M, Watanabe H, et al. An assessment of the ability of Submicron- and Micron-Size silicone oil droplets in dropped prefillable syringes to invoke Early- and Late-Stage immune responses. J Pharm Sci. 2019;108(7):2278\u201387.","journal-title":"J Pharm Sci"},{"key":"768_CR21","unstructured":"Paul\u2011Ehrlich\u2011Institut. Homepage \u2013 Beovu. Paul\u2011Ehrlich\u2011Institut [Internet]. [cited\u202f2024\u202fAug\u202f11]. Available from: https:\/\/www.pei.de\/SharedDocs\/arzneimittel\/sera\/EU-1-19-1417.html"},{"issue":"12","key":"768_CR22","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal Aflibercept (VEGF Trap-Eye) in wet Age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology"},{"issue":"16","key":"768_CR23","doi-asserted-by":"publisher","first-page":"13004","DOI":"10.3390\/ijms241613004","volume":"24","author":"BH Moon","year":"2023","unstructured":"Moon BH, Kim Y, Kim SY. Twenty years of Anti-Vascular endothelial growth factor therapeutics in neovascular Age-Related macular degeneration treatment. Int J Mol Sci. 2023;24(16):13004.","journal-title":"Int J Mol Sci"},{"key":"768_CR24","doi-asserted-by":"publisher","first-page":"1196033","DOI":"10.3389\/fimmu.2023.1196033","volume":"14","author":"M Medrano-Bosch","year":"2023","unstructured":"Medrano-Bosch M, Sim\u00f3n-Codina B, Jim\u00e9nez W, Edelman ER, Melgar-Lesmes P. Monocyte-endothelial cell interactions in vascular and tissue remodeling. Front Immunol. 2023;14:1196033.","journal-title":"Front Immunol"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00768-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:07:58Z","timestamp":1781622478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-025-00768-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["768"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00768-0","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data was collected as part of a comprehensive quality control programme from the routine clinical care of patients with nAMD and DME at the Eye Clinic Sulzbach, which has been in practice since 2022. The evaluation of the retrospective data on intravitreal injections was approved by the local IRB\/EC (Ethics Committee of the Saarland Medical Association, vote 221\/23) and conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Approved by the local IRB\/EC (Ethics Committee of the Saarland Medical Association, vote 221\/23); the requirement for written informed consent for publication was not required due to the retrospective design and full anonymization. No identifiable personal data or recognizable images are included.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}